Tukavo 150mg Tablet (Tucatinib): Advanced HER2-Specific Tyrosine Kinase Inhibitor Tukavo 150 mg Tablet is a highly specialized oral antineoplastic agent containing the active ingredient Tucatinib. Developed as a next-generation Tyrosine Kinase Inhibitor (TKI), Tukavo is specifically engineered to target the Human Epidermal Growth Factor Receptor 2 (HER2). It has become a cornerstone in the treatment of advanced HER2-positive breast cancers, offering new hope for patients, including those with difficult-to-treat brain metastases. Therapeutic Indications and Clinical Usage Tukavo 150 mg is utilized globally in advanced oncology settings for: HER2-Positive Metastatic Breast Cancer: Indicated for adult patients with advanced unresectable or metastatic HER2-positive breast cancer. It is typically used in a triple-combination regimen with Trastuzumab and Capecitabine. Brain Metastases Management: Tukavo is uniquely effective because it can cross the blood-brain barrier. It is indicated for patients with or without brain metastases who have received one or more prior anti-HER2-based regimens. RAS Wild-Type Colorectal Cancer: In specific regulatory jurisdictions, it is used in combination with Trastuzumab for adult patients with HER2-positive metastatic colorectal cancer that has progressed after standard chemotherapy. Mechanism of Action: How Tukavo 150mg Works Tukavo works through a highly selective process of intracellular signaling blockade: Selective HER2 Inhibition: Unlike older TKIs that target multiple receptors, Tucatinib is highly selective for the HER2 protein. This selectivity helps minimize “off-target“ side effects like severe skin rashes or diarrhea associated with EGFR inhibition. Phosphorylation Blockade: By binding to the internal domain of the HER2 receptor, it prevents the phosphorylation process. This effectively shuts down the downstream signaling pathways (like MAPK and PI3K/Akt) that tell the cancer cell to multiply. Synergistic Effect: When used with Trastuzumab (which binds to the outside of the cell), Tukavo provides a “dual blockade,“ attacking the HER2 signaling from both the inside and the outside of the cancer cell. Blood-Brain Barrier Penetration: Its small molecular structure allows it to reach the central nervous system, making it a vital tool for treating cancer that has spread to the brain. Dosage and Administration Guidelines Standard Dosage: The recommended dose is 300 mg (two 150 mg tablets) taken orally twice daily. Administration: Tablets must be swallowed whole. Do not chew, crush, or break the tablets. Consistency: Can be taken with or without food. It is best to take doses approximately 12 hours apart at the same time each day. Missed Dose: If a dose is missed or vomited, the patient should skip that dose and take the next one at the regularly scheduled time. Safety Profile and Professional Monitoring Treatment with Tukavo 150 mg requires close medical supervision: 1. Hepatotoxicity Monitoring Tukavo can affect liver function. Regular liver function tests (ALT, AST, and Bilirubin) are mandatory before starting treatment and every three weeks during therapy. 2. Gastrointestinal Support Diarrhea is a common side effect. Patients should be prepared with anti-diarrheal medications (like loperamide) and maintain high fluid intake. 3. General Side Effects Other commonly reported symptoms include fatigue, nausea, vomiting, stomatitis (mouth sores), and “hand-foot syndrome“ (redness or swelling of the palms and soles). 4. Embryo-Fetal Toxicity Tucatinib can cause fetal harm. Effective contraception is required for females of reproductive potential and their male partners during treatment and for at least one week after the final dose. Storage and Global Handling Temperature: Store at room temperature, 20°C to 25°C (68°F to 77°F). Original Packaging: Keep the tablets in their original container with the desiccant to protect them from moisture. Handling: Dispose of any unused Tukavo 3 months after opening the bottle. Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383

Tuccatinn 150mg Tablet (Tucatinib): Advanced HER2-Targeted Therapy & Global Export Guide Tuccatinn 150mg Tablet is a highly specialized oral kinase inhibitor containing Tucatinib. Developed as a breakthrough in targeted oncology, it is designed specifically to combat cancers that overexpress the Human Epidermal Growth Factor Receptor 2 (HER2) protein. Manufactured by BDR Pharmaceuticals, Tuccatinn offers a potent, high-quality option for patients requiring advanced line therapies. Therapeutic Indications & Clinical Usage Tuccatinn 150mg is primarily indicated for: HER2-Positive Metastatic Breast Cancer: Used in combination with Trastuzumab and Capecitabine for adult patients who have already received one or more anti-HER2-based regimens. It is notably effective for patients whose cancer has spread to the brain (brain metastases). HER2-Positive Colorectal Cancer: Combined with Trastuzumab for adult patients with RAS wild-type, HER2-positive unresectable or metastatic colorectal cancer that has progressed after standard chemotherapy. The Science: Mechanism of Action Unlike many other therapies, Tucatinib is a Tyrosine Kinase Inhibitor (TKI) that is highly selective for HER2. Selective Inhibition: It specifically targets the internal part of the HER2 receptor, blocking the signals that tell cancer cells to grow and multiply. Blood-Brain Barrier Penetration: One of the most significant advantages of Tuccatinn is its ability to cross the blood-brain barrier, making it a critical tool for treating secondary tumors in the brain. Synergistic Effect: When used with Trastuzumab and Capecitabine, it creates a “dual-blockade“ of the HER2 pathway, significantly improving progression-free survival. Dosage and Administration Guidelines Standard Dose: The recommended dose is typically 300mg (two 150mg tablets) taken orally twice daily. Administration: Tablets should be swallowed whole with water and can be taken with or without food. Consistency: Doses should be taken approximately 12 hours apart at the same time every day to maintain steady levels in the bloodstream. Missed Dose: If a dose is missed or vomiting occurs after taking a tablet, the patient should wait and take the next scheduled dose at the regular time. Safety Profile & Side Effect Management Patient safety is paramount. While Tuccatinn is a targeted therapy, it requires careful monitoring: Diarrhea Management: This is a common side effect. Patients are often advised to have anti-diarrheal medication (like Loperamide) ready at the start of treatment. If severe diarrhea occurs, medical intervention is necessary to prevent dehydration. Hepatotoxicity (Liver Health): Tuccatinn can affect liver enzymes. Oncologists will perform blood tests (ALT, AST, and Bilirubin) every 3 weeks during the initial phase of treatment to ensure liver health. Hand-Foot Syndrome: Some patients may experience redness, swelling, or pain on the palms and soles. Using thick moisturizers and avoiding hot water can help manage these symptoms. General Symptoms: Other common effects include nausea, fatigue, mouth sores (stomatitis), and decreased appetite. Storage and Handling Temperature: Store at room temperature, ideally below 30°C (86°F). Environment: Keep the tablets in their original container to protect them from moisture and light. Safety: Ensure the medication is kept out of reach of children and pets. Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383

TUCANAT 150 MG Tablet (Tucatinib) Exporter & Global Oncology Supplier – Ernest Oncology TUCANAT 150 MG Tablet is an advanced targeted anti-cancer medication containing Tucatinib, used primarily for the treatment of HER2-positive breast cancer, particularly in patients with advanced or metastatic disease. Ernest Oncology is a trusted pharmaceutical exporter from India, supplying TUCANAT 150 MG tablets globally to oncology hospitals, pharmaceutical distributors, cancer treatment centers, and medical procurement agencies. Pharmaceutical importers and healthcare providers across Washington (USA), London (UK), Riyadh (Saudi Arabia), Bangkok (Thailand), Canberra (Australia), Singapore, and Kingston (Jamaica) depend on Ernest Oncology for bulk supply of Tucatinib tablets with reliable global delivery and competitive export pricing. What is TUCANAT 150 MG Tablet? TUCANAT 150 MG Tablet contains Tucatinib, a targeted HER2 tyrosine kinase inhibitor used in combination therapy for the treatment of HER2-positive metastatic breast cancer. Tucatinib is designed to specifically block HER2 signaling pathways that promote cancer cell growth and tumor progression. This targeted therapy helps improve treatment outcomes when used alongside other anti-cancer medicines such as trastuzumab and capecitabine. Because of its clinical effectiveness, Tucatinib is considered a significant advancement in HER2-positive breast cancer therapy worldwide. Mechanism of Action The active ingredient Tucatinib works by selectively inhibiting the HER2 tyrosine kinase receptor, which plays a major role in the growth of certain breast cancer cells. By blocking HER2 signaling pathways, Tucatinib: • Prevents cancer cell growth and proliferation • Inhibits tumor progression • Enhances the effectiveness of combination therapies • Improves outcomes in HER2-positive metastatic breast cancer This targeted mechanism allows TUCANAT tablets to specifically attack cancer cells while minimizing damage to normal cells. Medical Uses of TUCANAT 150 MG TUCANAT tablets are primarily prescribed for: • HER2-positive metastatic breast cancer • Advanced breast cancer resistant to other treatments • Combination therapy with trastuzumab and capecitabine • Patients with brain metastases associated with HER2-positive cancer Tucatinib has become a critical targeted therapy medicine in modern oncology treatment programs. Product Information Product Name: TUCANAT 150 MG Tablet Generic Name: Tucatinib Strength: 150 mg Dosage Form: Oral Tablet Therapeutic Category: Anti-Cancer / HER2 Tyrosine Kinase Inhibitor Packaging: Blister Pack / Export Carton Packaging Shelf Life: 24–36 Months Storage: Store below 25°C in a cool and dry place Benefits of TUCANAT Tablets • Advanced targeted therapy for HER2-positive breast cancer • Helps slow tumor growth and progression • Effective in metastatic breast cancer treatment • Often used in combination with other cancer therapies • Oral tablet for convenient long-term treatment • Widely used in oncology hospitals and cancer treatment centers Why Choose Ernest Oncology ? Ernest Oncology is a leading pharmaceutical exporter from India, supplying high-quality medicines to pharmaceutical distributors, hospitals, and healthcare institutions worldwide. Key advantages include: • GMP certified pharmaceutical sourcing • Competitive export pricing for bulk buyers • Reliable global pharmaceutical distribution network • OEM and private labeling options available • Fast international delivery via DHL, Aramex & Air Cargo • Trusted supplier for oncology medicines and hospital drugs Export Documentation Provided Ernest Impex provides complete export documentation for international pharmaceutical shipments including: • Certificate of Analysis (COA) • Material Safety Data Sheet (MSDS) • Batch Release Certificate • Commercial Invoice • Packing List • Airway Bill / Shipping Documents • GMP Certificate • Certificate of Origin (if required) These documents ensure smooth customs clearance and regulatory compliance for pharmaceutical imports worldwide. 📞 Contact Ernest Oncology—Pharmaceutical Exporter from India [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD.] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 Direct WhatsApp https://wa.me/919359902383

Erlolieva 150mg Tablet: Targeted Epidermal Growth Factor Receptor (EGFR) Inhibition for Advanced Oncology Are you searching for a reliable Erlolieva 150 mg tablet exporter from India? Ernest Oncology, a specialized division of the Group of Ernest Pharmaceutical Pvt. Ltd., is a premier global supplier and bulk distributor of targeted tyrosine kinase inhibitors. We maintain an agile and secure supply chain for London (UK), Washington (USA), Canberra (Australia), and South Africa, ensuring that critical oncology medications reach institutional pharmacies with 100% pharmaceutical integrity. Detailed Product Profile: What is Erlolieva 150mg? Erlolieva 150mg is an oral targeted therapy containing the active pharmaceutical ingredient Erlotinib. Manufactured by Allieva Pharma Pvt Ltd, this 150mg tablet belongs to the class of medications known as EGFR Tyrosine Kinase Inhibitors (TKIs). It is a cornerstone treatment for patients with specific genetic mutations in non-small cell lung cancer and advanced pancreatic malignancies, designed to interrupt the molecular signals that drive cancer progression. 1. Therapeutic Indications Metastatic Non-Small Cell Lung Cancer (NSCLC): Used as first-line, maintenance, or second-line therapy for patients whose tumors have specific EGFR mutations (Exon 19 deletions or Exon 21 L858R substitution). Advanced Pancreatic Cancer: Used in combination with Gemcitabine for the treatment of patients with locally advanced, unresectable, or metastatic pancreatic cancer. Maintenance Therapy: Indicated for patients with locally advanced or metastatic NSCLC whose disease has not progressed after four cycles of platinum-based first-line chemotherapy. 2. Mechanism of Action: Reversible Receptor Blockade EGFR Targeting: It targets the Epidermal Growth Factor Receptor (EGFR), a protein on the surface of cells that normally helps them grow and divide. In many cancer cells, this receptor is overactive or mutated. ATP Competition: Erlotinib binds reversibly to the Adenosine Triphosphate (ATP) binding site of the receptor's intracellular tyrosine kinase domain. Signal Interruption: By blocking ATP, it prevents the phosphorylation process required to send growth signals to the nucleus, effectively stalling tumor cell proliferation and inducing apoptosis (programmed cell death). 3. Administration and Dosage Management Standard Dosing: The typical dose is 150 mg once daily for NSCLC and 100 mg once daily for pancreatic cancer (in combination with gemcitabine). Timing: Must be taken on an empty stomach, at least 1 hour before or 2 hours after a meal. Food significantly increases the bioavailability, which can lead to increased toxicity. Storage: Keep at room temperature, away from moisture and direct heat, in its original packaging. Clinical Side Effects & Safety Monitoring Dermatological Safety: An “acne-like“ rash is very common and often indicates the drug is working. Patients should also monitor for dry skin and nail changes. Gastrointestinal Health: Potential for diarrhea, nausea, and stomatitis. Severe diarrhea may require dose interruption or hydration therapy. Pulmonary Monitoring: Rare but serious risk of Interstitial Lung Disease (ILD). Patients should report any new or worsening cough or shortness of breath. Ocular Safety: Monitoring for corneal ulceration or perforation, especially in patients with a history of dry eyes. Drug Interactions: Avoid proton pump inhibitors (PPIs) and smoking, as both can significantly reduce the concentration of erlotinib in the blood. Why Source Erlolieva 150mg from Ernest Oncology? Verified Authenticity: Direct sourcing of Allieva Pharma’s Erlolieva with full batch-specific COA and traceability. Logistics Authority: Expert handling of complex import/export regulations for the USA, UK, Australia, and South Africa. Wholesale Solutions: Competitive bulk pricing for hospital groups, specialty pharmacies, and regional distributors. Regulatory Compliance: Every shipment includes GMP certificates and comprehensive B2B documentation to ensure global standards. 📞 Contact Ernest Oncology—Pharmaceutical Exporter from India [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD.] 🌐 Websites: www.oncologymedicinesupplier.com www.ernestimpex.com www.ernestvision.com www.ernestpharmaceuticals.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Direct Link: https://wa.me/919359902383

Nindalieva 150mg Capsule: Advanced Tyrosine Kinase Inhibition for Pulmonary and Oncology Management Are you searching for a reliable Nindalieva 150mg Capsule exporter from India? Ernest Oncology, a specialized division of the Group of Ernest Pharmaceutical Pvt. Ltd., is a premier global supplier and bulk distributor of advanced antifibrotic and antineoplastic therapies. We maintain an agile and secure supply chain for London (UK), Washington (USA), Canberra (Australia), and South Africa, ensuring that critical medications reach institutional pharmacies with 100% pharmaceutical integrity. Detailed Product Profile: What is Nindalieva 150mg? Nindalieva 150mg is an oral targeted therapy containing the active pharmaceutical ingredient Nintedanib. Manufactured by Allieva Pharma Pvt Ltd, this 150mg capsule is a potent small-molecule tyrosine kinase inhibitor (TKI). It is specifically engineered to block pathways involved in the progression of pulmonary fibrosis and the growth of specific types of lung tumors, making it a cornerstone in respiratory and oncology care. 1. Therapeutic Indications Idiopathic Pulmonary Fibrosis (IPF): Used to slow the decline in lung function in patients with chronic, progressive scarring of lung tissue. Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD): Indicated to slow the rate of decline in pulmonary function in patients with connective tissue disease-related lung involvement. Progressive Fibrosing Interstitial Lung Diseases (ILDs): For patients with a chronic fibrosing phenotype that continues to worsen despite treatment. Non-Small Cell Lung Cancer (NSCLC): In specific global regions, it is used in combination with Docetaxel for the treatment of advanced adenocarcinoma after first-line chemotherapy. 2. Mechanism of Action: Triple Kinase Inhibition Inhibition of Pro-Fibrotic Pathways: It targets Platelet-Derived Growth Factor Receptors (PDGFR), Fibroblast Growth Factor Receptors (FGFR), and Vascular Endothelial Growth Factor Receptors (VEGFR). Blocking Fibroblast Proliferation: By inhibiting these signaling pathways, it prevents the migration and transformation of fibroblasts, which are the primary cells responsible for lung scarring. Anti-Angiogenic Effect: In oncology, it interferes with the tumor’s ability to develop new blood vessels, effectively limiting the supply of nutrients required for tumor expansion. 3. Administration and Dosage Management Standard Dosing: The typical recommended dose is 150mg taken twice daily, approximately 12 hours apart. Administration: Capsules must be swallowed whole with food and a full glass of water. They should not be crushed or chewed due to the bitter taste and potential for irritation. Missed Dose: If a dose is missed, the patient should skip it and take the next dose at the scheduled time; double doses should be avoided. Clinical Side Effects & Safety Monitoring Gastrointestinal Health: Diarrhea and nausea are very common; hydration and anti-diarrheal management are often necessary. Hepatotoxicity: Drug-induced liver injury is a risk; Liver Function Tests (LFTs) must be conducted before starting and periodically during treatment. Cardiovascular Risks: Monitoring for arterial thromboembolic events (such as myocardial infarction) and hypertension. Pregnancy Warning: Nintedanib can cause fetal harm; effective contraception is mandatory for female patients of reproductive potential. Why Source Nindalieva 150mg from Ernest Oncology? Verified Authenticity: Direct sourcing of Allieva Pharma’s Nindalieva with full batch-specific COA and traceability. Logistics Authority: Expert handling of complex import/export regulations for USA, UK, Australia, and South Africa. Wholesale Solutions: Competitive bulk pricing for hospital groups, specialty pharmacies, and regional distributors. Regulatory Compliance: Every shipment includes GMP certificates and comprehensive B2B documentation to ensure global standards. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD.] 🌐 Websites: www.oncologymedicinesupplier.com www.ernestimpex.com www.ernestvision.com www.ernestpharmaceuticals.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Direct Link: https://wa.me/919359902383

Pariblieva 150mg Tablet: Advanced PARP Inhibition for Targeted Ovarian and Breast Cancer Therapy Are you looking for a verified Pariblieva 150mg Tablet exporter from India? Ernest Oncology, a specialized division of the Group of Ernest Pharmaceutical Pvt. Ltd., is a premier global supplier and bulk distributor of advanced targeted therapies. We facilitate a secure, high-standard supply chain for London & the UK, the USA, Australia, and South Africa, ensuring that critical PARP inhibitors reach oncology centers with 100% pharmaceutical integrity. Detailed Product Profile: What is Pariblieva 150mg? Pariblieva 150mg is an oral targeted therapy containing the active pharmaceutical ingredient Olaparib. Manufactured by Allieva, this 150mg tablet belongs to a revolutionary class of drugs known as Poly (ADP-ribose) Polymerase (PARP) inhibitors. It is specifically designed for patients with certain genetic mutations, offering a precision medicine approach to treating cancers that have become resistant to traditional chemotherapy. 1. Therapeutic Indications Ovarian Cancer: As maintenance treatment for adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Breast Cancer: For patients with germline BRCA-mutated (gBRCAm), HER2-negative metastatic breast cancer who have been previously treated with chemotherapy. Pancreatic Cancer: As maintenance treatment for adult patients with deleterious gBRCAm metastatic pancreatic adenocarcinoma. Prostate Cancer: For patients with metastatic castration-resistant prostate cancer (mCRPC) and specific gene mutations who have progressed following prior therapy. 2. Mechanism of Action: The Concept of Synthetic Lethality Inhibiting DNA Repair: PARP enzymes are responsible for repairing single-strand breaks in DNA. Pariblieva blocks these enzymes. Creating Double-Strand Breaks: When PARP is inhibited, single-strand breaks turn into double-strand breaks during cell replication. Synthetic Lethality: In normal cells, these breaks are repaired via “Homologous Recombination.“ However, in cancer cells with BRCA1 or BRCA2 mutations, this repair pathway is broken. The accumulation of DNA damage becomes too great, and the cancer cell dies, while healthy cells remain largely unaffected. 3. Administration and Dosing Standard Dosage: Typically 300 mg (two 150mg tablets) taken twice daily. Timing: Can be taken with or without food. Tablets should be swallowed whole and not chewed, crushed, or dissolved. Consistency: Maintaining a steady level of the drug in the system is vital for preventing cancer cell DNA repair. Clinical Side Effects & Safety Monitoring Hematological Toxicity: Potential for Anemia, Neutropenia, and Thrombocytopenia. Monthly blood counts (CBC) are recommended for the first year of treatment. Gastrointestinal: Nausea, vomiting, diarrhea, and loss of appetite are common, especially during the first few weeks. Fatigue: Significant tiredness or weakness (asthenia) is frequently reported. MDS/AML: In rare cases, PARP inhibitors have been linked to secondary bone marrow disorders; long-term monitoring of blood counts is essential. Pneumonitis: Rare but serious lung inflammation; patients should report any new or worsening respiratory symptoms immediately. Why Source Pariblieva 150mg from Ernest Oncology? Verified Authenticity: Direct sourcing of Allieva’s Pariblieva with full batch-specific traceability and COA. Logistics Authority: Expert handling of complex import regulations for London (UK), the USA, Australia, and South Africa. Bulk Supply Solutions: Competitive wholesale pricing for hospital groups, oncology networks, and regional distributors. Regulatory Compliance: Every shipment is accompanied by GMP certificates and complete B2B documentation to ensure the highest quality standards. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD.] 🌐 Websites: www.oncologymedicinesupplier.com www.ernestimpex.com www.ernestvision.com www.ernestpharmaceuticals.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Direct Link: Chat on WhatsApp

Brcaone 150mg Tablet (Olaparib): Precision PARP Inhibitor for Targeted Oncology Care Brcaone 150mg Tablet is a specialized, targeted anti-cancer medication featuring the active ingredient Olaparib. It belongs to a revolutionary class of drugs known as PARP (poly [adenosine diphosphate-ribose] polymerase) inhibitors. Manufactured by Bresure Care, Brcaone 150mg represents a breakthrough in precision medicine, specifically engineered to exploit genetic vulnerabilities in cancer cells—particularly those with BRCA mutations—to induce “synthetic lethality.“ Therapeutic Indications and Clinical Usage Brcaone 150mg is utilized globally for the management of advanced malignancies, specifically targeting cancers associated with BRCA1/BRCA2 gene mutations and homologous recombination repair (HRR) deficiencies: Advanced Ovarian Cancer: Used as a maintenance treatment for adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. HER2-Negative Metastatic Breast Cancer: Indicated for the treatment of adult patients with germline BRCA-mutated, HER2-negative metastatic breast cancer who have been previously treated with chemotherapy.Metastatic Pancreatic Cancer: Employed for the maintenance treatment of adult patients with germline BRCA-mutated metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen. Metastatic Castration-Resistant Prostate Cancer (mCRPC): Prescribed for patients with specific HRR gene-mutated mCRPC who have progressed following prior treatment with enzalutamide or abiraterone. Mechanism of Action: How Brcaone 150mg Works Enzyme Inhibition: PARP enzymes are essential for repairing single-strand breaks in DNA. Brcaone binds to and inhibits these enzymes. DNA Damage Accumulation: When PARP is blocked, single-strand DNA breaks transition into double-strand breaks during cell replication. Synthetic Lethality: In cancer cells with existing DNA repair deficiencies (like BRCA1/2 mutations), these double-strand breaks cannot be repaired, leading to genomic instability and programmed cell death (apoptosis). Selective Targeting: Because healthy cells have intact alternative DNA repair pathways, they are significantly less affected by Brcaone than cancerous ones, reducing systemic damage. Dosage and Administration Guidelines Standard Dosage: The typical adult dose is 300mg (two 150mg tablets) taken twice daily, totaling 600mg per day. Method of Intake: Tablets must be swallowed whole with water. They should not be chewed, crushed, dissolved, or divided. Timing: Can be taken with or without food. It is recommended to take doses approximately 12 hours apart to maintain steady therapeutic levels. Clinical Adjustments: Dosage may be modified by an oncologist based on individual patient tolerance, renal function, or to manage specific adverse reactions. Safety Profile and Professional Monitoring Hematological Monitoring: Common side effects include anemia, neutropenia (low white blood cells), and thrombocytopenia (low platelets). Regular Complete Blood Counts (CBC) are required before and during treatment. Gastrointestinal Support: Nausea, vomiting, and diarrhea are frequently reported. These are managed with supportive care and adequate hydration. Respiratory Vigilance: Patients should report any new or worsening shortness of breath or cough, as inflammation of the lungs (pneumonitis) can occur in rare cases. Embryo-Fetal Toxicity: Olaparib can cause fetal harm. Effective contraception is mandatory for both male and female patients of reproductive potential during treatment. Storage and Handling Instructions Temperature: Store at room temperature, 20°C to 25°C. Protection: Keep tablets in the original container to protect them from moisture and light. Safety: Caregivers should avoid direct skin contact with the tablets. Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383

Olpaza 150mg Tablet (Olaparib): Advanced PARP Inhibitor for Targeted Cancer Therapy Olpaza 150mg Tablet is a specialized, targeted anti-cancer medication containing the active ingredient Olaparib. It belongs to a revolutionary class of drugs known as PARP (poly [adenosine diphosphate-ribose] polymerase) inhibitors. Manufactured by Intas Pharmaceuticals Ltd., Olpaza 150mg represents a breakthrough in precision medicine, specifically designed to exploit genetic vulnerabilities in cancer cells to induce “synthetic lethality.“ Therapeutic Indications and Clinical Usage Olpaza 150mg is utilized globally for the management of advanced malignancies, particularly those associated with BRCA1/BRCA2 gene mutations: Ovarian Cancer: Used as maintenance treatment for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer in adult patients who are in complete or partial response to first-line platinum-based chemotherapy. Breast Cancer: Indicated for the treatment of gBRCA-mutated, HER2-negative metastatic breast cancer in patients previously treated with chemotherapy. Pancreatic Cancer: Employed for the maintenance treatment of adult patients with germline BRCA-mutated metastatic pancreatic adenocarcinoma whose disease has not progressed on first-line platinum-based chemotherapy. Prostate Cancer: Indicated for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene mutations. Mechanism of Action: How Olpaza 150mg Works Olpaza works by specifically targeting the DNA repair machinery within cancer cells: PARP Inhibition: PARP enzymes are essential for repairing single-strand breaks in DNA. Olpaza binds to and inhibits these enzymes. DNA Damage Accumulation: When PARP is blocked, single-strand DNA breaks transition into double-strand breaks during replication. Synthetic Lethality: In cancer cells with existing DNA repair deficiencies (like BRCA mutations), these double-strand breaks cannot be repaired, leading to genomic instability and programmed cell death (apoptosis). Sparing Healthy Cells: Because normal cells have intact alternative DNA repair pathways, they are significantly less affected by Olpaza than cancerous ones. Dosage and Administration Guidelines Standard Dosage: The typical adult dose is 300 mg (two 150 mg tablets) taken twice daily, totaling 600 mg per day. Administration: Tablets must be swallowed whole with water and should not be chewed, crushed, or dissolved. Flexibility: Can be taken with or without food. It is recommended to take doses approximately 12 hours apart at the same time each day. Dose Adjustments: Oncologists may modify the dosage based on individual patient tolerance, renal function, or the occurrence of specific side effects. Safety Profile and Side Effect Management As a potent targeted therapy, Olpaza 150mg requires professional clinical monitoring: 1. Hematological Monitoring Common side effects include anemia, neutropenia (low white blood cell count), and thrombocytopenia (low platelet count). Regular blood tests (CBC) are required before and during treatment. 2. Gastrointestinal Support Nausea, vomiting, and diarrhea are frequently reported. These are often managed with anti-emetic medications and by maintaining adequate hydration (8–10 glasses of water daily). 3. Respiratory Vigilance While rare, inflammation of the lungs (pneumonitis) can occur. Patients should report any new or worsening shortness of breath or cough immediately. 4. Embryo-Fetal Toxicity Olaparib can cause fetal harm. Effective contraception is mandatory for both female and male patients of reproductive potential during and for several months after the final dose. Storage and Handling Temperature: Store below 30°C in a dry place. Protection: Keep the bottle tightly closed and away from direct sunlight and moisture. Safety: Store out of reach of children and pets. Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383

The Professional Guide to Ibyra 150mg (Olaparib) Tablet: Targeted DNA Repair Inhibition & Global Supply In the evolving field of precision oncology, Ibyra 150mg Tablet has emerged as a significant advancement in the treatment of various solid tumors. As a leading pharmaceutical exporter from India, Ernest Oncology (Group of Ernest Pharmaceutical Pvt. Ltd.) facilitates access to this critical therapy for healthcare providers and patients in the USA, UK, UAE, Australia, Singapore, South Africa, Europe, the Middle East, Africa, and Asia. What is Ibyra 150mg (Olaparib)? Ibyra 150mg contains Olaparib, a potent, orally active PARP (poly [ADP-ribose] polymerase) inhibitor. PARP is a protein family involved in various cellular processes, most notably DNA repair. By inhibiting these enzymes, Ibyra exploits the genetic vulnerabilities of certain cancer cells, particularly those with existing DNA repair deficiencies. Therapeutic Indications Ibyra 150mg is globally utilized for the management and maintenance therapy of: Ovarian Cancer: Advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer, especially in patients with BRCA mutations or homologous recombination deficiency (HRD). Breast Cancer: HER2-negative, germline BRCA-mutated metastatic breast cancer. Prostate Cancer: Metastatic castration-resistant prostate cancer (mCRPC) with specific gene mutations (BRCA1, BRCA2, or ATM). Pancreatic Cancer: Maintenance treatment of germline BRCA-mutated metastatic pancreatic adenocarcinoma. Mechanism of Action Ibyra functions through a specialized process called synthetic lethality: DNA Repair Blockade: It inhibits PARP enzymes, which are essential for repairing single-strand DNA breaks. Double-Strand Breaks: When these single-strand breaks are not repaired, they lead to more complex double-strand breaks during DNA replication. Cancer Cell Death: In cells with BRCA mutations (which usually handle double-strand repair), the accumulation of DNA damage becomes overwhelming, leading to the selective death of cancer cells while sparing most healthy cells. Product Specifications & Clinical Usage Technical Specifications Active Ingredient: Olaparib (150 mg) Form: Oral Tablet (Film-coated). Manufacturer: Zydus Lifesciences (Marketed globally via Ernest Oncology). Packaging: Typically available in bottles of 60 tablets. Storage: Store at room temperature between 20°C to 25°C (68°F to 77°F). Keep in original packaging to protect from moisture. Dosage and Administration Method: Oral consumption. Tablets must be swallowed whole with water; do not crush, chew, or dissolve. Standard Schedule: Usually taken twice daily, with or without food. Consistency: It is recommended to take the doses at the same time each day to maintain steady therapeutic levels in the bloodstream. Safety & Side Effects Common side effects may include: Nausea and vomiting. Fatigue and weakness. Anemia (low red blood cell count). Diarrhea or indigestion. Important Safety Note: Regular blood tests (CBC) are required to monitor blood cell counts. Patients should avoid grapefruit and Seville oranges, as they can increase the drug's concentration in the body. Global Supply Chain Excellence by Ernest Oncology Exporting advanced oncology medications like Ibyra 150mg requires precise logistical management and regulatory compliance. Verified Global Distribution: We ensure the integrity of your shipment from our hubs in India to destinations like New York, London, Dubai, or Singapore. Bulk Supplier Advantage: We support oncology centers and pharmacy distributors in South Africa, Australia, and the USA with reliable stock availability and competitive B2B pricing. Documentation Support: Our team provides all necessary regulatory paperwork, including Certificate of Analysis (CoA) and Country of Origin (COO). 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383